Literature DB >> 9234755

Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response.

T Darville1, C W Andrews, K K Laffoon, W Shymasani, L R Kishen, R G Rank.   

Abstract

Whether there is a pathogenic or protective outcome to chlamydial infection may be defined by the host response. We infected C57BL/6 (C57) and C3H/HeN (C3H) mice with the human biovar of Chlamydia trachomatis, serovar E, and, in select experiments, with the mouse pneumonitis agent of C. trachomatis (MoPn). We compared the courses of infection, histopathology, and host responses that resulted from these infections. The duration of infection with either chlamydial biovar was significantly increased in the C3H strain of mice. The intensity of infection was examined in mice infected with serovar E, and it was significantly increased in the C3H strain. Histopathology revealed the incidence of severe hydrosalpinx to be significantly greater in C3H mice than in C57 mice. In contrast, severe distention of the uterine horns was observed in all infected C57 mice compared to none of the C3H mice infected with serovar E and only 25% of those infected with MoPn. Acute inflammation was significantly increased in the uterine horns of C57 mice compared to that of C3H mice. Examination of antigen-specific responses revealed qualitatively similar responses in the two strains. Determination of gamma interferon- versus interleukin 4- producing cells revealed the predominance of a Th1 response in both strains. Serum enzyme-linked immunosorbent assays for immunoglobulin G1 (IgG1) and IgG2a revealed a predominance of IgG2a antibody in both strains, although the levels of antibody were significantly greater in C3H mice. Lymphocyte proliferation studies revealed increased proliferation in the iliac nodes of both strains at 1 to 3 weeks after infection. Because of the early eradication of infection observed in the C57 strain, we explored the relative production of tumor necrosis factor alpha (TNF-alpha) in the two strains. TNF-alpha levels were significantly increased in the genital tract secretions of C57 mice compared to that of C3H mice during the first week of infection. Increased TNF-alpha may be beneficial to the host by leading to earlier eradication of infection, thereby preventing infection of the oviduct and thus the major disease sequelae associated with chlamydial infection of the genital tract.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234755      PMCID: PMC175432          DOI: 10.1128/iai.65.8.3065-3073.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

Review 1.  Genital chlamydial infections: epidemiology and reproductive sequelae.

Authors:  W Cates; J N Wasserheit
Journal:  Am J Obstet Gynecol       Date:  1991-06       Impact factor: 8.661

2.  The in vitro bactericidal activity of peritoneal and spleen cells from Listeria-resistant and -susceptible mouse strains.

Authors:  P R Wood; V Spanidis; K Frangos; C Cheers
Journal:  Cell Immunol       Date:  1986-04-15       Impact factor: 4.868

3.  Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis.

Authors:  S J Rasmussen; L Eckmann; A J Quayle; L Shen; Y X Zhang; D J Anderson; J Fierer; R S Stephens; M F Kagnoff
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

4.  Variation in virulence among oculogenital serovars of Chlamydia trachomatis in experimental genital tract infection.

Authors:  J I Ito; J M Lyons; L P Airo-Brown
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

5.  A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis.

Authors:  D M Williams; D M Magee; L F Bonewald; J G Smith; C A Bleicker; G I Byrne; J Schachter
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

6.  Salpingitis in mice induced by human strains of Chlamydia trachomatis.

Authors:  M Tuffrey; P Falder; J Gale; D Taylor-Robinson
Journal:  Br J Exp Pathol       Date:  1986-08

7.  Chlamydia trachomatis infections in the United States. What are they costing us?

Authors:  A E Washington; R E Johnson; L L Sanders
Journal:  JAMA       Date:  1987-04-17       Impact factor: 56.272

8.  Effect of prior sexually transmitted disease on the isolation of Chlamydia trachomatis.

Authors:  B P Katz; B E Batteiger; R B Jones
Journal:  Sex Transm Dis       Date:  1987 Jul-Sep       Impact factor: 2.830

9.  Chlamydia trachomatis infection of the Fallopian tubes. Histological findings in two patients.

Authors:  B R Møller; L Weström; S Ahrons; K T Ripa; L Svensson; C von Mecklenburg; H Henrikson; P A Mårdh
Journal:  Br J Vener Dis       Date:  1979-12

10.  Production of colony-stimulating factors during pneumonia caused by Chlamydia trachomatis.

Authors:  D M Magee; D M Williams; E J Wing; C A Bleicker; J Schachter
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

View more
  98 in total

Review 1.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Immunization with a peptide corresponding to chlamydial heat shock protein 60 increases the humoral immune response in C3H mice to a peptide representing variable domain 4 of the major outer membrane protein of Chlamydia trachomatis.

Authors:  V L Motin; L M de la Maza; E M Peterson
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  The recall response induced by genital challenge with Chlamydia muridarum protects the oviduct from pathology but not from reinfection.

Authors:  Melissa M Riley; Matthew A Zurenski; Lauren C Frazer; Catherine M O'Connell; Charles W Andrews; Margaret Mintus; Toni Darville
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

Review 4.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

5.  MyD88 deficiency leads to decreased NK cell gamma interferon production and T cell recruitment during Chlamydia muridarum genital tract infection, but a predominant Th1 response and enhanced monocytic inflammation are associated with infection resolution.

Authors:  Uma M Nagarajan; James Sikes; Daniel Prantner; Charles W Andrews; Lauren Frazer; Anna Goodwin; Jessica N Snowden; Toni Darville
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

6.  Acquired immunity to Chlamydia pneumoniae is dependent on gamma interferon in two mouse strains that initially differ in this respect after primary challenge.

Authors:  J M Vuola; V Puurula; M Anttila; P H Mäkelä; N Rautonen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

7.  Inflammasome-dependent caspase-1 activation in cervical epithelial cells stimulates growth of the intracellular pathogen Chlamydia trachomatis.

Authors:  Ali A Abdul-Sater; Evonne Koo; Georg Häcker; David M Ojcius
Journal:  J Biol Chem       Date:  2009-07-31       Impact factor: 5.157

8.  Effect of cold water-induced stress on immune response, pathology and fertility in mice during Chlamydia muridarum genital infection.

Authors:  Tesfaye Belay; Anthony Woart; Vincent Graffeo
Journal:  Pathog Dis       Date:  2017-07-31       Impact factor: 3.166

9.  Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model.

Authors:  Uma M Nagarajan; Daniel Prantner; James D Sikes; Charles W Andrews; Anna M Goodwin; Shanmugam Nagarajan; Toni Darville
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

10.  Mouse strain-dependent differences in susceptibility to Neisseria gonorrhoeae infection and induction of innate immune responses.

Authors:  Mathanraj Packiam; Sandra J Veit; Deborah J Anderson; Robin R Ingalls; Ann E Jerse
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.